Premium
Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale
Author(s) -
Hewer Sarah,
Varley Sue,
Boxer Adam L.,
Paul Eldho,
Williams David R
Publication year - 2016
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.26694
Subject(s) - progressive supranuclear palsy , rating scale , clinical global impression , depression (economics) , physical therapy , clinical trial , logistic regression , activities of daily living , psychology , physical medicine and rehabilitation , medicine , pediatrics , disease , pathology , developmental psychology , alternative medicine , economics , macroeconomics , placebo
Background Despite the widespread use of the Progressive Supranuclear Palsy Rating Scale (PSPRS), it is not known what change in this scale is meaningful for patients. Methods We analyzed data from a large clinical trial in PSP‐Richardson's syndrome (AL‐108‐231) to calculate minimal clinically important worsening. This was defined as the difference in mean change of PSPRS in subjects rated “a little worse” and those rated “unchanged” on the Clinicians' Global Impression of Change Scale. A multivariate analysis using logistic regression assessed the relationship between clinical worsening, PSPRS, depression, and activities of daily living. Results The minimal clinically important worsening on the PSPRS was 5.7 points, corresponding to the mean decline over 6 months in the trial. Changes in activities of daily living and PSPRS were significantly associated with clinical worsening. Conclusions Clinically meaningful change is measurable on the PSPRS over 6 months. © 2016 International Parkinson and Movement Disorder Society